The risk of venous thromboembolism is markedly elevated in patients with diabetes
- First Online:
- Cite this article as:
- Petrauskiene, V., Falk, M., Waernbaum, I. et al. Diabetologia (2005) 48: 1017. doi:10.1007/s00125-005-1715-5
- 992 Downloads
Diabetes mellitus is associated with several changes in coagulation and fibrinolysis that may lead to a thrombogenic propensity. However, it is not known whether these perturbations actually cause increased risk of venous thromboembolism.
In a retrospective population-based study we evaluated the medical records of all 302 adult patients who were admitted to the Umeå University Hospital with verified deep vein thrombosis or pulmonary embolism during the years 1997 to 1999. The patients were classified as diabetic (n=56) and non-diabetic (n=246) according to clinical information. The total number of diagnosed diabetic patients in different age groups in the catchment area was obtained from computerised registries in the primary health care centres and the Umeå University Hospital, and data on the background population were collected from the Swedish population registry.
The annual incidence rate of venous thromboembolism among diabetic patients in the population was 432 per 100,000 individuals (95% CI 375–496). In non-diabetic individuals it was 78 (95% CI 68–88). The age-adjusted incidence rate among the diabetic population was 274 (95% CI 262–286). The annual incidence rate of venous thromboembolism was elevated in type 1 and type 2 diabetic patients and the incidence rates were 704 (95% CI 314–1,566) and 412 (95% CI 312–544) respectively. The overall standardised morbidity ratio was 2.27 (95% CI 1.75–2.95), i.e. diabetic patients were more prone to venous thromboembolism after adjustment for age differences.
These results suggest that the age-adjusted risk for venous thromboembolism is more than two-fold higher among diabetic patients than in the non-diabetic background population.
KeywordsDeep vein thrombosisDiabetes mellitusIncidence ratePulmonary embolismVenous thromboembolism
Deep vein thrombosis
Standardised morbidity ratio
There is increasing evidence that diabetes mellitus is associated with several defects of coagulation and fibrinolysis that lead to a procoagulant, thrombogenic predisposition . Raised concentrations of fibrinogen, von Willebrand factor and other endothelium-derived mediators increase blood viscosity and promote platelet activation and adhesion. In addition, fibrinolysis is impaired by raised concentrations of plasminogen activator inhibitor-1. It is not known whether there is a generalised increased thrombotic tendency or whether the adverse haemostatic impact of diabetes is confined to the arterial tree, where it can contribute to the well-known increase in cardiovascular events [1–4]. If there is a generalised tendency for thrombus formation in the vasculature, diabetes would be expected to lead to an increased risk of venous thromboembolism (VTE), too. However, despite the great scientific interest in diabetic vascular complications, little is known about the risk of VTE in diabetic patients and data about this remain controversial. A few studies have suggested that diabetes is a significant risk factor for VTE [5, 6], but some studies suggest that diabetes does not increase the risk of thromboembolic events [1, 7, 8].
In the present retrospective study, we address the incidence of venous thromboembolism, i.e. deep vein thrombosis (DVT) and pulmonary embolism (PE), in the Umeå University Hospital catchment area during 3 years, 1997–1999, and we show that the risk of VTE among diabetic patients is greater than in the non-diabetic population.
Subjects and methods
We analysed the medical records of patients who had episodes of VTE during the years 1997 to 1999 and were admitted to the Departments of Medicine or Cardiology at the Umeå University Hospital. All adult patients in the catchment area (population ≥15 years=110,100) with diagnosis codes I80, I82 and I26 according to ICD, but excepting isolated superficial thrombophlebitis, were included. All VTE patients were hospitalised at the University Hospital during this time period. Subjects with post-surgery (<4 weeks) VTE and patients not resident in the catchment area were excluded.
Clinical characteristics of diabetic and non-diabetic patients with venous thromobembolism (VTE)
Type of VTE
Deep vein thrombosis
Coronary heart disease
Congestive heart failure
Arrhythmia (atrial fibrillation or flutter)
Diagnosis of DVT and PE
DVT (n=219) was diagnosed by Doppler ultrasonography (182 patients/83.1%), phlebography (21/9.6%), or both of these methods (7/3.2%). For seven patients (3.2%) DVT diagnosis was only clinical. Urography was used to diagnose renal vein thrombosis and computerised tomography for cava inferior thrombosis (one patient/0.5% for each).
PE (n=83) was diagnosed using angiography (41 patients/49.4%), ventilation/perfusion scintigraphy together with chest X-ray (14/16.9%), autopsy (11/13.3%) or a combination of these methods (6/7.2%). In several cases, PE was diagnosed using other methods such as clinical presentation only (8/9.6%), computerised tomography (1/1.2%), plasma-d-dimers (1/1.2%), cardiac ultrasound and arterial blood gas (1/1.2%)).
Evaluation of incidence
To evaluate the incidence of VTE, we obtained information from the Swedish population registry on the total number of inhabitants divided by age groups and sex in the catchment area (at the end of 1998). Data on the number of adult (≥15 years) patients diagnosed with diabetes were collected from computerised patient registries in the primary health care centres and the Departments of Medicine and Cardiology at Umeå University Hospital, giving an ascertainment greater than 95%, as virtually all adult diabetic patients in the area attend these units. In 1998, 284 type 1 and 4,041 type 2 diabetes patients were identified. This gives a prevalence of 0.26 and 3.67%, respectively among adults, which is consistent with previous results from northern Sweden . Screening studies report somewhat higher numbers as they include asymptomatic subjects .
The Student’s paired t-test and chi square test were used for comparisons between the diabetic and non-diabetic groups, and a p value of less than 0.05 was considered significant. Incidence was calculated as incidence rate (IR) (cases per 100,000 adult inhabitants/year) and given with 95% CIs. In addition, for the diabetic population, IRs were also age-adjusted according to the age distribution of the non-diabetic population. The standardised morbidity ratio (SMR) was calculated to address age-adjusted risk associated with diabetes.
Incidence rates of venous thromboembolism (VTE) and risk measures for the diabetic versus non-diabetic population
IR in non-diabetic subjects
IR in diabetic subjects
Age-adjusted IR in diabetic subjects
Among non-diabetic VTE patients an isolated DVT diagnosis was more common than in diabetic VTE patients (75.2 and 60.7%, respectively, p=0.03), but the annual age-adjusted IR for DVT was still higher in diabetic than in non-diabetic subjects, 194 (95% CI 190–198) and 58 (95% CI 50–67) respectively, and the age-adjusted SMR for diabetic subjects was 1.9 (95% CI 1.2–3.0). Accordingly, diabetic VTE patients had PE significantly more often than non-diabetic VTE patients (39.3 and 24.8%, respectively, p=0.018) and the age-adjusted IR for PE was much higher in diabetic patients than in the non-diabetic population, 80 (95% CI 77–83) and 19 (95% CI 15–25), respectively with an SMR of 19.9 (95% CI 13.1–30.3).
The presence of other clinical conditions that might contribute to the risk for VTE is shown in Table 1. Diabetic patients had coronary heart disease, hypertension and congestive heart failure significantly more often then non-diabetic individuals. Of the women, six used oral contraceptive pills, one of whom had type 2 diabetes. Two non-diabetic women developed DVT during pregnancy.
During hospitalisation for VTE, 25 patients (8.3%) died. In the group of patients admitted to the hospital for DVT three patients died, all three non-diabetic. In contrast, the mortality of diabetic patients versus non-diabetic was higher in the event of PE, though the difference was not statistically significant (nine patients/40.9% and 13/21.3%, respectively). This could be partly explained by the higher age among diabetic patients. There was no significant difference in post-hospitalisation mortality in diabetic versus non-diabetic patients during follow-up until June 2002.
In this pilot study we show that diabetes is a possible risk factor for VTE, as the age-adjusted incidence of DVT and PE was significantly higher in the diabetic than in the non-diabetic population. The increased VTE risk in diabetes patients could be due to the diabetic state itself, or to other risk factors that are associated with diabetes. Possibly, both explanations are true.
There are several well-established risk factors for VTE, including immobilisation, surgery, cancer and age [11, 12]. The risk of VTE is dramatically increased in the later decades of life  and we also found that the incidence of VTE, in particular DVT, increased with age. In this study, diabetic patients with VTE were significantly older then non-diabetic patients and that may suggest that the higher risk in diabetic subjects is mainly due to older age. However, by using SMR to adjust for age differences, we demonstrated that there is an age-independent, more than 2-fold risk elevation among diabetic patients, and this was also substantiated by incidence numbers in separate five-year age groups and by the age-adjusted IRs.
It is recognised that cancer is one of the major risk factors for VTE , but we did not find any clear difference in the prevalence of diagnosed cancer between diabetic and non-diabetic VTE patients. Venous stasis associated with prolonged immobilisation is also an important risk factor for VTE , but there was no significant difference in the frequency of documented immobilisation between diabetic and non-diabetic patients suffering VTE. Congestive heart failure is an independent risk factor for VTE, and this is related to the degree of impairment of left ventricular ejection fraction . In our study, the proportion of subjects with congestive heart failure was greater among the diabetic patients, probably partly as a consequence of hypertension and CHD. Cardiac failure leads to venous stasis and this, in combination with abnormalities in haemostasis and in platelet and endothelial function, should predispose diabetic subjects to development of venous thrombosis . Moreover, obesity which is common in type 2 diabetes, could be an important factor and smoking might also be involved, but complete data were not available in this investigation.
The fact that diabetes leads to a greater increase in risk of PE than in risk of DVT suggests that diabetes not only has an impact on the development of venous thrombi, but also on the progression to a more severe condition with the detachment of emboli ending up in the pulmonary arteries. Diabetes, in particular type 2, is believed to affect fibrinolysis more severely than coagulation, and that could possibly have a greater impact on the occurrence of symptomatic PE vs DVT. Although type 2 diabetes in particular is considered to be strongly linked to dysregulated haemostasis, our present data suggest that type 1 diabetes is an equally strong risk factor for VTE. Hence the diabetic state itself appears to be important, but this should be examined in detail in larger studies.
There is very limited information in the previous literature about the associations between diabetes and VTE. The Framingham Study found no relationship between glucose levels and the occurrence of VTE . In contrast, a longitudinal study that investigated associations between cardiovascular risk factors and incidence of VTE showed that diabetes and obesity were each associated with significantly increased risk of VTE independently of age, race and sex. Those with diabetes at baseline had a 1.7-fold greater risk (95% CI 1.2–2.4) than those with normal fasting glucose levels . In the transplantation literature diabetes has been reported to be an important risk factor for VTE [6, 16]. In a retrospective study on patients undergoing kidney transplantation multivariate analysis identified diabetes as a significant risk factor for DVT (OR 2.0) and for PE (OR 2.6) , results which are compatible with our present findings in the general population. In addition, Bergqvist et al. in a prospective study on VTE following kidney transplantation identified diabetes as the most important risk factor .
We recognise that there are limitations in the present study that might have influenced the results. Methods verifying events of VTE vary between physicians, and both false positive and false negative results occur. Our case-finding may not be quite complete and, in addition, many VTE episodes are subclinical. Taken together, these circumstances might lead to under- or overestimation of the true number of cases in both the diabetic and non-diabetic cohorts. On the other hand, our overall IR is similar to other results . Another problem in the study is that the number of diabetic patients in the total population as well as among VTE subjects may be underestimated because only those clinically diagnosed as having diabetes were considered as diabetic subjects. However, none of the above considerations is expected to markedly alter the finding of a higher incidence of VTE among the diabetic patients. In the future, hopefully, a large prospective population-based study including a detailed characterisation of glucose tolerance will help to further clarify the relationship between diabetes and VTE, as well as the specific roles of factors such as hyperglycaemia, insulin resistance, type of diabetes and comorbidities.
In conclusion, we found that the age-adjusted risk of venous thromboembolism among diabetic patients is about two-fold higher than in non-diabetic subjects. The underlying mechanisms are not quite clear and it is not known whether the risk is explained mainly by diabetes itself or by concomitant conditions.
Financial support was given by the Swedish Research Council (Medicine, 14287), the Swedish Diabetes Association and the Faculty of Medicine at Umeå University. We thank Hjordis Andersson and Pia Roslin for help with the evaluation of patient records.